Thesis
MoonLake Immunotherapeutics (MLTX) cratered ~90% after Phase 3 VELA-2 disappointment and is now trading near all-time/52-week lows. The panic flush reset options pricing: Vega is cheap; Delta is reset. Our plan is to buy long-dated calls now and harvest the pre-catalyst IV ramp, closing before earnings or major updates. Core contract: ~500 DTE $10C (Δ≈0.60, high OI/liquidity, strong Vega).
Targets/Rules
- Profit target: +80% (base), stretch: +100–110%
- Max hold: 2 months → if not working, roll, don’t hold and bleed
- Risk: Allocate ≤2% of portfolio to this idea
What the Charts Say (context for the options trade)
- Momentum washout: RSI plunged to extremely oversold on 3M/1Y/All-time; MACD shows heavy bearish cross but short-term histogram flattening (typical into a reflex bounce).
- Structural damage: All key supports snapped; any rally is a repair bounce, not an instant trend reversal.
- Setup relevance: Post-crash regimes often see implied volatility rebuild over the 2–6 weeks ahead of earnings/updates—exactly the edge we’re aiming to monetize.
News Catalyst Wrap (why the reset happened)
- Catalyst: Company reported disappointing Phase 3 results (VELA-2, sonelokimab) → institutional de-risking and gap-down collapse.
- Aftermath: Multiple firms (e.g., Hagens Berman, Holzer & Holzer, Faruqi & Faruqi, BFA Law) announced shareholder/class-action investigations, adding headline pressure.
- What it means for options: After the event shock, IV/vega were crushed; historically, IV rebuilds into the next scheduled update. We’re positioning to buy IV low and sell IV high ahead of that date.
Analyst Price Targets (street reset)
- Post-crash cuts:
- Needham → $20
- Guggenheim → $20
- RBC → $10 (Sector Perform)
- Jefferies → $8 (Hold)
- Pre-crash context: PTs in $62–$100 range (GS/Wainwright/Needham/RBC) are now obsolete.
Read: Street now implies a single-digits to low-teens trading band near term, with a recovery optionality case (upper bound $20) if the pipeline narrative stabilizes.
Insider Trading Read-Through
- Director sale: One director sold ~23,500 shares @ ~$48.79 (pre-collapse) — optics are poor and will be cited in suits.
- CSO/admin moves: Conversions/returns showed administrative activity, not open-market buys.
- No “buy-the-dip” by insiders post-crash → no visible insider confidence yet. This reinforces that any near-term upside is more technical/IV-driven than fundamental.
Options Flow (Calls) — is positioning bullish or bearish?
Oct 17, 2025 (17 DTE):
- Big OI $7.5C (~11,655) and $10C (~6,538) → speculative bounce positioning close to spot.
Dec 19, 2025 (80 DTE): - Largest cluster $12.5C (~3,051) → market eyeing a stabilization toward low teens.
Feb 20, 2026 (143 DTE): - Notable OI at $22.5C (~2,347) plus $25–30C tails → lottery-ticket recovery bets.
Verdict: Call-side OI clusters skew bullish/hopeful (short-term bounce + longer-dated upside speculation). It’s not classic institutional conviction—more tactical/speculative—but it supports our pre-catalyst IV/Delta plan.
Financial Snapshot (risk lens)
- Revenue TTM: $0 (clinical-stage)
- FCF TTM: –$166.8M (heavy burn)
- Current Ratio: ~16.7 (ample near-term liquidity)
- Debt/Equity: ~0.21 (low leverage)
Read: Balance sheet buys time, but dilution risk remains if pipeline progress stalls. This is precisely why we trade the pre-catalyst IV rather than invest for a distant commercialization.
The Trade — LEAPS to Buy Vega Low, Sell Vega High
Contract: ~500 DTE $10 Call (Δ≈0.60, high OI/liquidity, higher Vega than deep-ITM)
Why $10C?
- Δ≈0.60 provides 3–5× sensitivity to stock moves
- Vega meaningfully higher vs. deeper ITM → best to monetize IV ramp
- One of the highest liquidity strikes on the LEAPS board
What we’re monetizing:
- IV/Vega expansion into earnings/pipeline update, and
- Δ-assisted bounce from a historically oversold state.
Exit: BEFORE earnings (avoid IV crush). Targets: +80% base, +100–110% stretch.
3-Batch Scaling Plan (very important)
- Batch 1 — Enter Now: Buy the ~500 DTE $10C.
- Batch 2 — Add Later: If the options price of Batch 1 pulls back –40–50% (of the options price) within 1–2 weeks, add the second batch.
- Batch 3 — Add Later: If the options price of Batch 2 falls another –40–50% (of the options price) in the following 1–2 weeks, add the third batch.
Note: The –40–50% triggers refer strictly to the options price, not the stock price.
Max Hold: 2 months. If we’re not near targets or IV hasn’t expanded, roll (same strike/next cycle or adjust strike to re-center Δ≈0.55–0.65).
Monitoring Checklist
- IV trend: IV percentile rising? (should advance 2–4 weeks pre-event)
- Price momentum: RSI back >30; MACD crossover on daily
- Flow: Does call-side OI migrate higher (e.g., $10 → $12.5)?
- Liquidity: Spreads tight enough (≤5–10% of premium) for exits
- Calendar: Confirm earnings/updates window and exit ahead of it
Final Word
MLTX is a binary biotech whose equity just reset. That’s exactly the regime where pre-catalyst volatility trades can shine. The ~500 DTE $10C gives us the best mix of vega + delta + liquidity to exploit the IV rebuild, with a disciplined 3-batch plan, tight risk, and a hard no-earnings-hold rule.
⚠️ Risk Disclosure / Allocation Guardrails
This content is for educational purposes only and not financial advice. Options are risky and can lose 100% of the premium. Limit exposure to no more than 2% of total portfolio per this speculative idea, use only risk capital, and follow the plan to close prior to the catalyst to avoid IV crush.
